ANTIPLATELET TREATMENTS. JL DAVID Unité Thrombose- Hémostase CHU Liège
|
|
- Beatrix Harrington
- 5 years ago
- Views:
Transcription
1 ANTIPLATELET TREATMENTS JL DAVID Unité Thrombose- Hémostase CHU Liège 1
2 INDICATIONS OF ANTIPLATELET DRUGS. Ischemic stroke TIA. unstable / stable amgina myocardial infarction percutaneous coronary intervention ( stenting ) Coronary Artery By-pass Graft. peripheral arterial disease 2
3 3
4 IMPACT OF ANTIPLATELET DRUGS. COX-1 prostaglandins synthesis Aspirine and other anti-cox 1. thromboxane receptor. P2Y12 - ADP receptor Ticlopidine, Clopidogrel. GPIIb-IIIa receptor Abciximab / Integrilin / Fibans ( Tiro-, Frada-, Lami- ) 4
5 METABOLISM OF ASA 1/ rapid absorbtion in stomach and upper small intestine ( enteric form intestine ) partial déacétylation fasting: min. / post-prandial : +/- 2h 2/ into contact with platelets in portal circulation contact ASA platelets irreversible inhibition of TXA2 synthesis 3/ deacetylation in liver and in plasma : half-life of ASA min. salicylic acid : no antiplatelet effect 5
6 PHARMACOLOGICAL PROPERTIES OF ASA irreversible inhibition of COX-1 CH 3 -OH Ser polypeptide PGH synthase no inhibition of Hydroxyperoxydase prevention of TXA2 production inhibition of. Endothelin ETA receptor platelet aggregation vasoconstriction. T cells adhesion and transmigration on endothelium. NFκB activation including that induced by Chlamydia pneumoniae on EC 6
7 DURATION OF THE ANTIPLATELET EFFECT OF ASA irreversible inhibition of platelets 8-10 d production of new platelets depending on consumption 10 % / d reappearance of thrombotic risk recovery of hemostatic potential 2 d 3-4 d 7
8 METABOLISM OF ARACHIDONIC ACID 8
9 INHIBITION OF PROSTACYCLINE BY ASA. acetylation of platelet COX -1 in portal circulation. half-life ½ de l ASA in circulation 20 min impact of ASA in portal > systemic circulation. de novo synthesis of endothelial COX-1 transient inhibition of PGI2 production = no reduction of urinary 6-kéto PGF1a / 24 h ( Inhibition dose-dependent?) 9
10 LIMITS OF THE ANTITHROMBOTIC EFFECTS OF ASA ASA is a antiplatelet agent blocking only TXA2 dependent aggregation. no inhibition of platelet adhesion. no or poor inhibition of platelet aggregation induced by strong stimuli. very weak inhibition of COX-2 inductible following inflammatory and mitogen stimuli 10
11 RISK FACTORS OF ATHEROTHROMBOSIS > 65 years old * overweight * smoking hypertension * diabetes * hypercholestérolemia* LDL / hypo- HDL hyperhomocysteinemia inflammatory diseases familal history of premature myocardial infarction* * criteria of PPP 11
12 PRIMARY PREVENTION Studies end-point RR CI 95% PHS 1989 IM 0,56 0,45-0,70 Meta-anal CV 0,85 0,78-0,94 PPP 2001 CV 0,77 0,62-0,95 mort. CV 0,56 0,31-0,99 12
13 INDICATIONS OF ASA FOR PRIMARY PREVENTION Eur.Soc. Hypert.-Eur. Soc. Card.2003 hypertension (controlled ) in > 50 years old and risk of CV event or creatinine > 1.3 mg/dl Am.Diab. Ass 2002 diabetes and 30 y.o. or add.cv risk High risk of CV event > 3% (Eu) or >/=10% (USA) 13
14 SECONDARY PREVENTION BY AA pts at high risk ( > 3% /y ) : AMI, UA,SA, past-mi, IS, TIA, PAD, FA RRR vasc. event -1/4 nonfatal IM - 1/3 non fatal stoke - 1/4 vascular death - 1/6 Antithrombotic Trialist Collaboration
15 SECONDARY PREVENTION traitement abs.reduction / 1000 MI 2 y - 36 MI 1 mo - 38 stroke/ TIA 2 y - 36 stroke 1 mo - 9 stable angin. 2 y - 22 periph art.. atr. fibrill. 15
16 ASA DOSES acute event prevention mgr mg / daily 325 mg every other day enteric form 90% bioavailable additive dose- dépendent effect mg / 24 h Interference with Ibuprofen, Naproxen,.! 16
17 ASA IN WOMEN Secondary prevention ASA effective in both sexes but benefit related to CV risk Primary prevention ( Women s Health study) ASA 100 mg /alt.day vs placebo 10 years in women >/= 45 y.o. major CV events - 9 % strokes - 17 % isch. strokes - 24 % MI ns except in sub-group >/= 65 y.o CV deaths ns Ridker et al. NEJM
18 ASA and SEX Women s Health Study (ASA 100mg / alt.d) Physician s Health Study ( ASA 325 mg /alt.d) In the placebo group rate / p/yr MI stroke ratio MI/ stroke
19 RESISTANCE TO ASPIRIN. clinical trials ASA treatment is statistically effective but no apparent prevention in a great number of patients. ex vivo tests aggregometry, PFA, P-selectin expression, insufficient effect in % to % of the treated patients depending on the population studied, the assay utilized and the criteria of resistance McKee SA et al. Thromb Haemost
20 RESISTANCE TO ASPIRIN : WHAT DOES IT MEAN? Relationship between ex-vivo testing of some pharmacological effects and the clinical issue? Need for increasing the dosage or for shifting to an alternative treatment? 20
21 CLINICAL OUTCOME OF PATIENTS WITH RESISTANCE TO ASA Aspirin treated patients in case-control study from HOPE trial urin. conc. of 11-dehydroTXB2 OR for MI, stroke or CV death p upper/ lower quartile 1.8 ( ) OR for MI upper quartile 2 ( ) OR for CV death upper quartile 3.5 ( ) < Eickelboom JW et al. Circulation
22 POSSIBLE CAUSES OF RESISTANCE TO AAS Extrinsic mechanisms. hyperstimulation of platelets hyperreactive platelets ( increased turn-over). insufficient dosage lack of information about individual dose-effect relationship. interference with other inhibitors of COX-1 ( ibuprofen,..) McKee S.A et al. Thromb Haemost Haluska MK and Halushka PV Circulation
23 Intrinsic mechanisms POSSIBLE CAUSES OF RESISTANCE TO AAS. bypass of inhibited platelet COX-1 by PGH2 shunted into platelets from nucleated cells in which COX-1 has been regenerated. induction of COX-2 insensitive to ASA in platelets, monocytes and macrophages allowing for TXA2 production. polymorphism of COX-1 affecting the response to ASA. other polymorphism(s) regulating platelet activity. expression of COX-2 messenger RNA (controversial). PLA2 allele greater affinity of GPIIbIIIa receptor for fibrinogen McKee S.A et al. Thromb Haemost Haluska MK and Halushka PV Circulation
24 AGGREGATING EFFECTS OF ADP ADP released from activated platelets, red cells, EC platelet receptors tyrosine phosphorylation of proteins P2Y1 Gq protein PLc activation Ca release aggregation P2Y12 Gi2 protein adenylcyclase inhibition camp full aggregation and release amplification of the response to other agonists and recruitment of other platelets 24
25 25
26 PHARMACOLOGICAL PROPERTIES OF THIENOPYRIDINES Ticlopidine Clopidogrel (T carboxy methylated in benzilic position ) active metabolite covalent modification of the receptor P2Y12 inhibition of. ADP binding GPIIbIIIa activation fibrinogen binding bridges between platelets. P- selectin expression of platelets platelet - monocyte / platelet - neutrophil conjugate formation Storey et al. Thromb Haemost
27 Muller I et al. Heart
28 CAPRIE Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events Clopidogrel 75 mg/j vs ASA 375 mgr/j pt for 1,91 years. IS in the past 6 mo. MI within 35 days of randomization. APAD annual composite risk = MI, IS, vascular death 28
29 CAPRIE Clopidogrel vs ASA history of annual risk (%) selected sub-groups p IS MI PAD total % ( IC 95% ) 5.83 % 5.32 % 29
30 30
31 CAPRIE clopidogrel vs ASA Reduction in composite IS-MI-VD or re-hospitalization for ischemia or bleeding RRR (%) ARR (%) NTT Total previous CABG >/= 1 isch.event mult.vasc.beds diabetes insulin-dep hypercholesterolemia
32 CURE Clopidogrel in Unstable angina to prevent Recurrent Events pt previously treated by AAS by 3-12 mo </= 100 or 101-<200 or >/=200 mg/ d within 24 h of symptom onset of ACS without - ST elevation : + placebo vs + clopidogrel 300mg then 75 mg/d composite risk = MI, IS, CVD 32
33 CURE ASA mg/d + placebo % + clopidogrel % RRR IC 95% 300 mg 75mg/d ,5 8,6 0, < 200 9,8 9,5 0, ,6 9,8 0, ASA. no more protective effect > 100 mg/j. bleeding risk hémorragique related to dose Clopidogrel. significant benefit for 12 mo greatest in patients with high TIMI high score or previous revascularization ( RRR 45%). increased risk of bleeding 33
34 PCI CURE Percutaneous Coronary Intervention - Sub group of pts from CURE PCI 1/ pretreatment clopidogrel 300 mg vs placebo + AAS 75 à 325 mg 2/ post - PCI ( stents 80%) clopidogrel 75 mg / d + AAS for 2-4 weeks 3/ then clopidogrel 75 mg / d vs placebo CVD, IM after +/- 8 mo 34
35 PCI CURE placebo % clopidogrel % RRR p 30 d 59 (6,4) 38 ( 2,9) 0,66 ( 0,44-0,99 ) mo 108 ( 8 ) 79 (6 ) 0,75 ( 0,56-1 ) pré-post 169 (12,6) 116 (8,8) 0,69 ( 0,54-0,87)
36 CURE and PCI-CURE AAS (%) ASA + Clopidogrel (%) RRR ARR NNT CURE 11,4 9,3 20 2,1 48 PCI-CURE 12,6 8,8 31 3,
37 ENHANCED RISK REDUCTION WITHCLOPIDOGREL Subgroups might be more responsive to clopidogrel than to ASA CAPRIE not pre-specified overestimation? previous CABG history of >/= 1 ischemic event involvement of multiple vascular beds diabetes hypercholesterolemia CAPRA patients with atherosclerosis are at much higher risk compared with those enrolled in clinical trials such as CAPRIE more likely to derive benefit CURE not pre-specified overestimation high TIMI risk score history of revascularization PCI-CURE prespecified from CURE 37
38 CREDO Clopidogrel to Reduce Events During Observation pts pré-pci post-pci 28j 12 mo Gp 1 clopid.300 clopid. 75 mg/d clopid. 75 mg/d + ASA mg/d ASA mg/d Gp2 - clopid. 75 mg/d - + ASA mg/d ASA mg/d composite risk of death MI, stroke 38
39 CREDO Composite risk of death, MI, stroke Gp1 Gp2 RRR % IC 95% p 8,5 11,5 26,9 3,9-44,
40 40
41 PLATELET GP RECEPTORS ( Integrins ) ADHESION GP Ib / IX / V vwf GP VI collagen GP Ia/ IIa collagen AGGREGATION GPIIbIIIa fibrinogen binding (defect in Glanzmann s thrombasthenia) = complex cross-talking between the various integrins 41
42 STRUCTURE AND PROPERTIES of GP IIb IIIa INHIBITORS Abciximab ( ReoPro) Fab fragment of a humanized murine mab (c7e3) also recognizing the vitronectin receptor αvβ3 (EC ; SMC) and the leucocyte integrin αmβ2 Tirofiban ( Aggrastat ) small mol.weight synthetic non-peptide ( tyrosine derivative) containing the RDG sequence of fibrinogen (= 2 binding sequences) Eptifibatide ( Integrilin ) cyclic synthetic heptafibatide containing the KGD sequence of fibrinogen ( = 1 binding sequence) 42
43 PHARMACODYNAMICS OF GP IIb IIIA INHIBITORS During infusion equilibrium between platelet receptors ( pl. number ) and plasma according to the affinities for platelet GPIIb IIIa / plasma half-life KD in nm min. abciximab tirofiban eptifibatide
44 PHARMACODYNAMICS OF GP IIb IIIa INHIBITORS After the end of infusion delay of functional recovery of platelets. abciximab h but detectable bound to platelets more than 2 weeks. tirofiban 30 min - 4 h. eptifibatide idem 44
45 OPTIMAL DOSES OF GPIIbIIIa INHIBITORS For an optimal efficiency in Acute Coronary Intervention a high and sustained level of receptor blockade is required > 80 % ( determined in animal experiences) > 90% : high risk of bleeding! 45
46 BENEFICIAL PROPERTIES OF GPIIbIIIa INHIBITORS AT THERAPEUTIC LEVEL ANTITHROMBOTIC PROPERTIES. inhibition of the final common pathway of platelet aggregation fibrinogen and vwf binding to GPIIbIIIa complex. inhibition of platelet procoagulant activities prothrombinase / platelet - derived microparticules. inhibition of phenotypic resistance to APC by activated platelets 46
47 BENEFICIAL PROPERTIES OF GPIIbIIIa ANTAGONISTS AT THERAPEUTIC LEVEL ANTIINFLAMMATORY PROPERTIES. suppression of CD 40 L expression by platelets. suppression of platelet- leucocytes aggregates. blunting of the raise of CRP, IL6, TNFα occurring h after PCI 47
48 SIDE-EFFECTS OF GPIIbIIIa INHIBITORS AT SUB -THERAPEUTICAL DOSAGE. partial agonist effect ( platelet escape ). increase of CD 40 ligand able to mediate GPIIbIIIa binding. increase of P-selectin expression worse outcome in PCI 48
49 OPTIMAL TIMING FOR INITIATION OF GPIIbIIIa INHIBITORS ISAR- COOL In patients with UA ( - ST depression or elevated troponin T level ) treated by an intense antiplatelet treatment ( ASA + Clopidogrel + Tirofiban) and Heparin, deferral of intervention ( 3-5 days ) vs less than 6 hours does not improve the composite 30 days incidence ( large non fatal MI or death from any cause) RR p 0.04 in favour of early intervention Neumann et al. JAMA
50 THROMBOCYTOPENIA DUE TO GPIIbIIIa ANTAGONISTS.Thrombocytopenia due to GP IIbIIIa antagonist < to < platelets / µl onset from 1 h ( within 24h ) to days after exposure to abciximab % * tirofiban eptifibatide lamifiban Control of platelet count : within the first 2-4h after the onset of the treatment and at least daily during treatment Lincoff et al. J Am Coll Card Diff.diagnosis:.EDTA-induced pseudothrombocytopenia corrected in citrated blood.heparin-induced thrombocytopenia 50
Clopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationFigure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE
CHAPTER 13 ASPIRIN Action Aspirin Resistance Aspirin Dose Therapeutic Efficacy - Secondary prevention - Acute coronary syndromes - Primary prevention Limitations and Side Effects Aspirin Aspirin should
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationPlatelet function testing in cardiovascular diseases
Hematology, 2005; 10 Supplement 1: 132 /137 PLATELET DISORDERS Platelet function testing in cardiovascular diseases ALAN D. MICHELSON From the Center for Platelet Function Studies, Departments of Pediatrics,
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationOral Anticoagulant Drugs
Oral Anticoagulant Drugs Spoiled sweet clover caused hemorrhage in cattle(1930s). Substance identified as bishydroxycoumarin. Initially used as rodenticides, still very effective, more than strychnine.
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationC.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial
Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationCase presentation 1: Mr F. is a
CLINICIAN UPDATE Platelet Function Testing in Cardiovascular Diseases Alan D. Michelson, MD Case presentation 1: Mr F. is a 60-year-old man with unstable angina who takes aspirin, 81 mg/day. A platelet
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationCarlo Patrono, MD, FESC. New York, 8 th December Catholic University School of Medicine, Rome, Italy. New York Cardiovascular Symposium
Aspirin in Primary and Secondary Cardiovascular Disease Prevention. Still Four Questions: About Enteric-Coated, Indicated Doses, Use in Diabetes, Use in PVD Carlo Patrono, MD, FESC Catholic University
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationClinical Aspects of Platelet Inhibitors and Thrombus Formation Telly A. Meadows and Deepak L. Bhatt. doi: /01.RES
Clinical Aspects of Platelet Inhibitors and Thrombus Formation Telly A. Meadows and Deepak L. Bhatt Circ Res. 2007;100:1261-1275 doi: 10.1161/01.RES.0000264509.36234.51 Circulation Research is published
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationPOCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine
POCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine Jackie Coleman, Ph.D. Director of Scientific Affairs Accumetrics, Inc. San Diego, CA Goals
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationDifferences In Efficacy Of Antiplatelet Therapy-Is That Gender Specific?
Differences In Efficacy Of Antiplatelet Therapy-Is That Gender Specific? DR.O.SAI SATISH PROFESSOR DEPARTMENT OF CARDIOLOGY NIMS Death is inevitable but Premature death is not Sir Richard Doll Topic outline
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationPlatelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
More informationDo We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
More informationArteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante
Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationProf. Jindřich Špinar, MD
Prof. Jindřich Špinar, MD Head of the Internal Cardiology dpt., University Hospital Brno Focuses on clinical cardiology, acute and chronic heart failure, ischemic heart gisease, hypertension Vice head
More informationP 2 Y 12 Receptor Inhibitors
P 2 Y 12 Receptor Inhibitors Clopidogrel, Prasugrel and Ticagrelor Which Drug and for Whom? Cheol Whan Lee, MD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationAcute Coronary Syndrome. ACC/AHA 2002 Guidelines
Acute Coronary Syndrome ACC/AHA 2002 Guidelines ACS Unstable Angina Non ST elevation MI ST elevation MI ACS UA and Non STEMI described in these guidelines Management of STEMI described in separate guidelines
More informationChapter 15 Glycoprotein IIb/IIIa Antagonists
Chapter 15 Glycoprotein IIb/IIIa Antagonists Introduction - GP IIb/IIIa receptors - Pharmacologic approaches - Preparations and dosages Mechanism of Action Clinical Efficacy - UA / NSTEMI - STEMI - PCI
More informationLa Trombosi Arteriosa
La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationMayor lung resection in the presence of anti-platelet therapy. Hans-Beat Ris Service de Chirurgie Thoracique CHUV, Lausanne
Mayor lung resection in the presence of anti-platelet therapy Hans-Beat Ris Service de Chirurgie Thoracique CHUV, Lausanne THORACIC SURGERY IN THE PRESENCE OF ANTI-PLATELET THERAPY Charybdis: Thrombosis
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationCollectively, the efficacy of the intravenous glycoprotein
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists A Meta-Analysis of Phase III Multicenter Randomized Trials Derek P. Chew, MBBS; Deepak L. Bhatt, MD; Shelly Sapp, MS; Eric J. Topol,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationCoronary thrombosis is a fundamental event in the pathophysiology of atherosclerotic coronary
Coronary disease ANTIPLATELET TREATMENT IN STABLE CORONARY ARTERY DISEASE c PLATELETS Correspondence to: Dr Charles C Knight, London Chest Hospital, Bonner Road, London E2 9JX, UK; knightlch@aol.com Charles
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More information- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e
-1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationConflicts of interest. Very balanced Lilly and team, AZ and BMS
Conflicts of interest Very balanced Lilly and team, AZ and BMS Distal microcirculation receives platelet microparticles Release TxA 2 and plugs microcapillaries Healthy vascular endothelium Prevents (antithrombotic
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationCurrent Treatment Of Ischemic Heart Disease In the United States: An Overview. By Dr Gary Mo
Current Treatment Of Ischemic Heart Disease In the United States: An Overview By Dr Gary Mo 1 Ischemic Heart Disease in the US 1. Cardiovascular disease remains the most common cause of death and is responsible
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationAntiplatelet Therapy. Briain Mac Neill
Antiplatelet Therapy Briain Mac Neill Galway University Hospital & National University of Ireland Galway Milestones in ACS Management Anti-Thrombin Rx Heparin LMWH Bivalirudin Anti-Platelet Rx Aspirin
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationNewer Antiplatelets. Asha Moorthy, Jain T Kallarakkal, James Kumar P INTRODUCTION
ewer Antiplatelets Asha Moorthy, Jain T Kallarakkal, James Kumar P ITRODUCTIO Many therapeutic drugs have been identified that possess clinically important antiplatelet activity. Platelet inhibition can
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationSESSION 5 2:20 3:35 PM
SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationAntiplatelet Therapy After PCI: How Much and How Long?
Antiplatelet Therapy After PCI: How Much and How Long? Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Antiplatelet Therapy after PCI: How much and how long? The simplest and extreme response: Give
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationClopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
More informationMINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationThe use of percutaneous coronary intervention (PCI) as
Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Jeffrey J. Popma, MD; Peter Berger, MD; E. Magnus Ohman, MD, FCCP;
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
More informationAntiplatelet therapy and Coronary Interventions. Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003
Antiplatelet therapy and Coronary Interventions Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003 Objectives Pharmacology of GP IIb/IIIa inhibitors and Monitoring of Platelet Inhibition
More informationPlatelet resistance is best defined as a lack of the desired pharmacologic effect
2Chapter 1 Anti-Platelet Resistance Oral Antiplatelet Therapy Resistance: Definition, diagnosis, and clinical implications Saurabh Gupta, MD Peter J. Casterella, MD Executive Summary Platelet resistance
More informationAntiplatelet in diabetics: strong but incomplete umbrella
Antiplatelet in diabetics: strong but incomplete umbrella Seung-Whan Lee, MD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Global Projections for the Number
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationIssues in the Management of Diabetic Patients with Cardiovascular Disease
Issues in the Management of Diabetic Patients with Cardiovascular Disease Elliot Rapaport, MD December 13, 2008 1 Hyperglycemia and Acute Coronary Syndromes 2 Effect of Hyperglycemia in STEMI Impairs microvascular
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationJOINT MEETING OF CORONARY REVASCULARIZATION 2014 TIONG LEE LEN SENIOR RESEARCH PHARMACIST CLINICAL RESEARCH CENTER, SARAWAK GENERAL HOSPITAL
The Effect of Non Steady State and Steady State Clopidogrel Carboxylic Acid Plasma Concentration on Clopidogrel Responsiveness in Patients Planned For Percutaneous Coronary Intervention JOINT MEETING OF
More informationDiabete ed ASA: cosa c è di nuovo?
Università Magna Græcia di Catanzaro Dipartimento di Medicina Sperimentale e Clinica Cattedra di Medicina Interna ed U.O. Malattie Cardiovascolari Scuola di Specializzazione in Geriatria Prof. Francesco
More informationDawn Matherne Meyer PhD,RN,FNP-C. Assistant Professor University of California San Diego
Dawn Matherne Meyer PhD,RN,FNP-C Assistant Professor University of California San Diego Evidence Based Care of the Stroke Patient: A Focus on Acute Treatment, BP Management, & Antiplatelets TIME IS BRAIN
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationLa terapia antiaggregante nel paziente con stroke
La terapia antiaggregante nel paziente con stroke Paolo Gresele Dipartimento di Medicina, Sez. Medicina Interna e Cardiovascolare Università di Perugia XXVII Congresso Nazionale FCSA Milano, 20-22 Ottobre
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More information